JP2018518980A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518980A5
JP2018518980A5 JP2017568322A JP2017568322A JP2018518980A5 JP 2018518980 A5 JP2018518980 A5 JP 2018518980A5 JP 2017568322 A JP2017568322 A JP 2017568322A JP 2017568322 A JP2017568322 A JP 2017568322A JP 2018518980 A5 JP2018518980 A5 JP 2018518980A5
Authority
JP
Japan
Prior art keywords
cancer
aurora
group
patient
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017568322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518980A (ja
JP6786530B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039195 external-priority patent/WO2017003845A1/en
Publication of JP2018518980A publication Critical patent/JP2018518980A/ja
Publication of JP2018518980A5 publication Critical patent/JP2018518980A5/ja
Application granted granted Critical
Publication of JP6786530B2 publication Critical patent/JP6786530B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017568322A 2015-07-02 2016-06-24 オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー Active JP6786530B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188113P 2015-07-02 2015-07-02
US62/188,113 2015-07-02
PCT/US2016/039195 WO2017003845A1 (en) 2015-07-02 2016-06-24 Biomarkers of response to selective inhibitors of aurora a kinase

Publications (3)

Publication Number Publication Date
JP2018518980A JP2018518980A (ja) 2018-07-19
JP2018518980A5 true JP2018518980A5 (https=) 2019-07-18
JP6786530B2 JP6786530B2 (ja) 2020-11-18

Family

ID=57609075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568322A Active JP6786530B2 (ja) 2015-07-02 2016-06-24 オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー

Country Status (4)

Country Link
US (2) US20190194750A1 (https=)
EP (1) EP3317427B1 (https=)
JP (1) JP6786530B2 (https=)
WO (1) WO2017003845A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10146914B1 (en) * 2018-03-01 2018-12-04 Recursion Pharmaceuticals, Inc. Systems and methods for evaluating whether perturbations discriminate an on target effect
JP7437648B2 (ja) * 2019-10-21 2024-02-26 学校法人順天堂 Ｌａｔｓ２変異疾患のための分子標的及びその利用
CA3192215A1 (en) * 2020-08-18 2022-02-24 Sherlock Biosciences, Inc. Hybridisation-based sensor systems and probes
CN112530518A (zh) * 2020-12-04 2021-03-19 湖南大学 基于k均值模型的动态自适应癌症突变簇识别方法
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
CN116334024A (zh) * 2022-12-07 2023-06-27 北京大学 极光激酶b基因k85和k87突变及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2602330A1 (en) * 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2018518980A5 (https=)
Lipsyc et al. Impact of somatic mutations on patterns of metastasis in colorectal cancer
JP2018532736A (ja) チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
JP2019511907A (ja) 癌免疫療法の治療標的としての患者特異的ネオエピトープのハイスループット同定
JP2016169229A5 (https=)
JP2017502686A5 (https=)
ES3023842T3 (en) Methods for prostate cancer detection and treatment
CA2937051A1 (en) Biopsy-driven genomic signature for prostate cancer prognosis
Bogusz et al. Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Uemura et al. Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer
Xu et al. SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy
Zhu et al. Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11 cancer types
Deng et al. Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer
JP2018531620A5 (https=)
Schubert et al. Germline variant affecting p53β isoforms predisposes to familial cancer
JP2011527575A5 (https=)
Turhal et al. Prevalence of K-Ras mutations in hepatocellular carcinoma: AA Turkish Oncology Group pilot study
Korak et al. Unlocking the potential of RARRES1: a pan-cancer analysis for prognosis, diagnosis, tumor immunity and drug sensitivity.
Mi et al. Prognostic biomarker in advanced gastric cancer
Chuensumran et al. Prognostic value of DNA alterations on chromosome 17p13. 2 for intrahepatic cholangiocarcinoma
Bertucci et al. “Wnt/β-Catenin in GIST”
Wong et al. Novel Cancer Immunotherapies
Wong et al. Novel Cancer Immunotherapies and Molecular Biomarkers in Head and Neck Cancer
Singh et al. Discovery of 1, 3, 5-triazine-monastrol based novel EGFR-tyrosine kinase inhibitor against human lung carcinoma
Polivka et al. 386P Oncogenic fusions in CNS gliomas assessed by next generation sequencing: The real-world experience